The industry is at a pivotal point in drug development and DCTs. Many sponsors are embracing DCT strategies, but there is a clear need to move away from individual point systems and disconnected data flow to a scalable, cohesive approach to truly achieve the next level of drug development speed.
By focusing on scaling their approach to implementing digital capabilities, sponsors can ensure long-term success and achieve a positive ROI, while finally giving patients the flexibility in choice we’ve only just talked about. But to achieve scale, digital strategies need to be embedded early into the pipeline, requiring the creation of standardized processes and an ecosystem of partners who work together to achieve a common goal.
Watch the on-demand panel discussion between Medable, Syneos, Illingworth and Veeva, moderated by Gilead, as they discuss how the next generation of clinical development is now.